[ETON]

Eton Pharmaceuticals stock price recorded a historical high of $64.29, which suggests positive momentum as a favorable event. If the stock price stably breaks through the resistance line at $64.00 and the upward trend continues, I will consider taking profits at $64.00. Conversely, if it breaks below the support line at $40.61 and the downward trend continues, I will execute a stop-loss at $40.61 to minimize capital loss. Technically, RSI is at 75.4 in the overbought zone and moving near the $64.00 resistance level, so I will watch for profit-taking and adjustment rather than additional purchases. At the entry point on 2026-09-08, I confirmed positive news regarding the all-time high of 64.29 USD. I observed that the candle flow rebounded somewhat to the September 8 closing price of 59.0 USD after the sharp drop on September 4 (low of 56.93). Technically, the moving average alignment is maintained, suggesting the uptrend could continue. I considered buying because the current price (approx. 59.0 USD) is below the resistance level of 64.00 USD, indicating upside potential. This is because I judged that the current price is not sufficiently distant from the support level of 40.61 USD, limiting the room for a stop-loss. (Note: Caution is needed regarding the RSI 75.4 overbought signal.) Technical indicators at the entry point show RSI(14) at 75.4 in the overbought zone, with moving averages in a golden cross indicating an upward trend. Volume is 0.97 times the 20-day average, close to average levels. The recent 7-day change rate is +52.6%, showing high volatility. At the prediction timing, positively reflecting the all-time high (64.29 USD) catalyst and the moving average golden crossover, along with the distance from the current price (approx. 59.0 USD) to the resistance level (64.0 USD), a modest rise (1.2%) was predicted; however, the actual result was a failure, resulting in a -10.5% loss (stop-loss triggered). Factors accounted for included the existence of catalyst news and the rise of short-term trends, while missed points were the strong overbought warning of RSI 75.4, the decreasing trend of biotech theme news (17 vs 34), and the weak resilience after the sharp drop on September 4 (closing price 59.0 on September 8). In particular, not sufficiently pre-reflecting the risk of falling below the support line of 40.61 USD proved to be a significant lesson. In the next trade, even if there is positive news, I will refrain from buying in RSI overbought territory of 75 or higher, or set tighter stop-loss levels. Furthermore, when theme news is in a decreasing trend, even if there is positive news, I will consider the possibility of market reaction slowing down, and break the habit of ignoring technical indicators (especially volume at 0.97x level) based solely on news positives. If the actual price fails to break through the resistance line (64.0 USD), I will execute stop-loss quickly, reflecting the need for multiple indicator confirmations rather than relying on a single positive news like the past similar case (August 14th +43.4%). The pre-history of this stock and past successful similar cases are as follows. First, selected by the keyword 'Eton Pharmaceuticals' overlap, the case on August 14, 2026 (+43.4%, earnings news) and the case on August 22 (+12.3%, all-time high news) show, like the current trading, an individual tendency for ETON to positively react to the stock price when major news (earnings, all-time high) occurs. In the pre-history, the pattern of a +50.8% surge on August 11, followed by a repeat of +9.5% on August 14, and a -2.1% adjustment on August 24, shows a flow going through a correction period after a short-term surge, and has structural characteristics similar to the candle flow before this entry (September 4 sharp drop followed by a rebound). On the other hand, the VEEE case on July 16, 2026 (+451.7%, M&A announcement) is difficult to compare directly because its [selection ground] states 'no direct similarity grounds (for reference as a top-performer)', but it is worth referencing as a top-performer case.

Eton Pharmaceuticals reached an all-time high of 55.07 USD, according to reports. If an additional upward trend continues, I will take profits at $50.18. Conversely, if downward pressure increases and the baseline breaks, I will cut losses at $37.0 to manage risk. (The take-profit and stop-loss prices are based on REPORTING calculations.) Based on the recent 7-day stock price fluctuations and trading volume, which are at 1.19 times the 20-day average, entry can be considered. The RSI(14) is at 44.8, indicating a neutral range, the moving averages are in a bullish alignment, the trading volume is 1.19 times the 20-day average, and the recent 7-day volatility has recorded -11.0%. We set a forecasted return of 1.5% and took a conservative approach; however, the actual result recorded a 12.3% increase, resulting in an OVERHIT designation. At the entry point, the RSI(14) was at a neutral indicator of 44.8, with trading volume at 1.19 times the 20-day average, and a -11.0% volatility over the past 7 days led us to expect a short-term rebound. However, stronger-than-expected buying pressure resulted in a larger increase. It is disappointing that the number of thematic news articles decreased to 51, reflecting a downward trend compared to previous periods, yet it did not adequately capture the price elasticity associated with the individual stocks' new highs. Through this trading, we learned that stocks near their all-time highs should not be definitively limited on the upside solely based on technical indicators in a neutral zone or the overall trend of decreasing news (falling) for the theme. In future scenarios of similar breakout to new highs, we will reflect a more flexible assessment of the increase in trading volume and the speed of volatility recovery to diversify our execution plans for setting profit-taking targets.

Eton Pharmaceuticals saw its stock price surge following the announcement of strong Q2 results and guidance for 2026. In the context of a strong upward trend, I will consider taking profits if the price reaches around the 20-day high resistance level of $50.18, and I will respond with a stop-loss if the 20-day low support level of $37.00 is breached. The current price of $40.80 is positioned above the 20-day low support level of $37.00, and considering the potential for a rebound with increased trading volume after an excessive short-term decline, one might consider entering with the expectation of upward potential towards the 20-day high resistance level around $50.18. The RSI(14) is at 44.8, indicating a neutral level, while the moving averages are in a bullish alignment. The trading volume is 1.19 times the 20-day average, and the recent 7-day volatility is recorded at -11.0%. At the time of the forecast, a rebound was anticipated with volume from the upper support level of the 20-day low ($37.00), setting the profit-taking target at the 20-day high resistance level of $50.18. Attention was drawn to the RSI(14) of 44.8 and the recent 7-day volatility of -11.0%, indicating an oversold condition. However, the actual outcome exhibited a much stronger upward trend, achieving a return of 43.4%, resulting in an OVERHIT designation. The announcement of Q2 earnings and the 2026 guidance acted as positive catalysts, and additional strong momentum was confirmed with the stock price reaching a new high on August 14, 2026, along with an upward revision of the target price, significantly surpassing the initial resistance level. Rather than relying solely on the technical basis of short-term overselling and support rebounds, it is essential to remain open to upward expansion when positive news and upward target price reports combine with real-time momentum. In future similar overselling rebound phases, if accompanied by strong fundamental news, I will reflect strategic flexibility in adjusting profit-taking targets upward in the next trades.